Education
About Us
Working with TipRanks
Follow Us
Mannkind Corp. (MNKD)
NASDAQ:MNKD
MNKD Stock Chart & Stats
$3.04
-$0.05(-0.80%)
At close: 4:00 PM EST
$3.04
-$0.05(-0.80%)
Day’s Range― - ―
52-Week Range$2.94 - $6.51
Previous CloseN/A
Volume434.88K
Average Volume (3M)5.37M
Market Cap
$935.08M
Enterprise Value$904.05M
Total Cash (Recent Filing)$171.35M
Total Debt (Recent Filing)$46.97M
Price to Earnings (P/E)179.6
Beta0.94
Next Earnings
May 13, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding308,100,430
10 Day Avg. Volume9,154,869
30 Day Avg. Volume5,372,022
Financial Highlights & Ratios
PEG Ratio-3.69
Price to Book (P/B)-33.97
Price to Sales (P/S)4.97
P/FCF Ratio126.60
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue2.59
Enterprise Value/Gross Profit3.39
Enterprise Value/Ebitda17.39
Forecast
1Y Price Target
$7.58Price Target Upside149.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.01
Revenue Forecast (FY)$453.07M
Bulls Say, Bears Say
Bulls Say
Commercial ExecutionManagement expanded the commercial organization and added dedicated account managers to drive hospital protocol adoption, which could accelerate Afrezza and other product sales and improve market penetration.
Pediatric Label ExpansionEnrollment in a pediatric Afrezza trial coupled with an updated mealtime dosing label could enable access to pediatric insulin patients and materially expand Afrezza's addressable market.
Product Innovation And Cost EfficiencyRegulatory approval and rollout of a Furoscix autoinjector that enables rapid subcutaneous IV-equivalent dosing and lowers manufacturing costs could boost margins and create an independent revenue stream.
Bears Say
Competitive Threat To Royalty StreamNew inhaler formulations from United Therapeutics, including a soft mist device that may reduce coughing versus dry powder inhalers, could shift prescribing away from Tyvaso dry powder inhaler and reduce related royalty income.
Dosing And Perceived Effectiveness ConcernsReal‑world reports tying Afrezza's limited effectiveness to under‑dosing underscore the need for clearer dosing guidance, which if unaddressed could slow adoption and hinder sales growth.
Partner Commercialization DependenceReliance on external commercialization partners for key products creates risk that partner decisions or prioritization could limit market access and cap upside for royalty and sales streams.
MannKind News
MNKD FAQ
What was Mannkind Corp.’s price range in the past 12 months?
Mannkind Corp. lowest stock price was $2.94 and its highest was $6.51 in the past 12 months.
What is Mannkind Corp.’s market cap?
Mannkind Corp.’s market cap is $935.08M.
When is Mannkind Corp.’s upcoming earnings report date?
Mannkind Corp.’s upcoming earnings report date is May 13, 2026 which is in 70 days.
How were Mannkind Corp.’s earnings last quarter?
Mannkind Corp. released its earnings results on Feb 26, 2026. The company reported -$0.05 earnings per share for the quarter, missing the consensus estimate of $0.017 by -$0.067.
Is Mannkind Corp. overvalued?
According to Wall Street analysts Mannkind Corp.’s price is currently Undervalued.
Does Mannkind Corp. pay dividends?
Mannkind Corp. does not currently pay dividends.
What is Mannkind Corp.’s EPS estimate?
Mannkind Corp.’s EPS estimate is >-0.01.
How many shares outstanding does Mannkind Corp. have?
Mannkind Corp. has 308,100,430 shares outstanding.
What happened to Mannkind Corp.’s price movement after its last earnings report?
Mannkind Corp. reported an EPS of -$0.05 in its last earnings report, missing expectations of $0.017. Following the earnings report the stock price went down -7.429%.
Which hedge fund is a major shareholder of Mannkind Corp.?
Currently, no hedge funds are holding shares in MNKD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MannKind Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.58 (149.45% Upside)
$7.58 (149.45% Upside)
Blogger Sentiment
Bullish
MNKD Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 26.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.2%
Last 30 Days ▲ 1.6%
Last 30 Days ▲ 1.6%
News Sentiment
Bearish
Bullish news 32%
Bearish news 68%
Bearish news 68%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-37.28%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
101.14%
Trailing 12-Months
Company Description
Mannkind Corp.
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
MNKD Company Deck
MNKD Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue performance driven by Tyvaso DPI and Afrezza, alongside strategic growth initiatives such as the acquisition of scPharmaceuticals. However, challenges such as a decline in VGo revenue and increased SG&A expenses were noted. Overall, the positive aspects of revenue growth and strategic acquisitions outweighed the lowlights.View all MNKD earnings summariesMNKD Stock 12 Month Forecast
Average Price Target
$7.58
▲(149.45% Upside)
Technical Analysis
Ownership Overview
2.92% Insiders
11.24% Mutual Funds
7.94% Other Institutional Investors
62.22% Public Companies and Individual Investors